SpaceX Fell 3.9% on Its Third Lockup Release Since the IPO. I'd Wait to Buy the Stock.

SpaceX shares fell 3.9% to $147.55 as up to 319 million employee and early-investor shares exited lockup on Sept. 9, with another 59.1 million affiliate shares becoming eligible the following day. Only about 2.2 billion of 13.6 billion shares outstanding, or 17%, are currently tradable, while roughly 3.1 billion additional shares are set to unlock by early December, including a 1.3 billion-share release after Q3 earnings. The stock trades at roughly $2 trillion, or more than 60x annualized Q2 revenue of about $31 billion, despite Q2 revenue nearly doubling to $7.8 billion and a $541 million net loss; potential $15.5 billion of index-fund buying tied to Nasdaq-100 rebalancing may offset some near-term supply.

Analysis

SPCX is entering the most fragile phase of a high-multiple IPO: the investable float is expanding faster than the natural holder base can form. The near-term index-rebalance bid may temporarily mask that imbalance, but passive demand is a one-time event while successive unlocks create recurring inventory overhang. A larger float also improves borrow availability, making hedged shorts and volatility-selling strategies more feasible after the initial passive-flow window.

The key catalyst is not an unlock date in isolation but the interaction between third-quarter results and the subsequent large release. If results merely meet expectations, early holders gain a liquid exit into a market already pricing unusually long-duration execution; if results disappoint on launch cadence, Starlink monetization, or capex intensity, the valuation has little fundamental cushion. The relevant 1-3 month risk is a self-reinforcing decline: lower prices reduce the incentive for incremental growth buyers while increasing employee/early-investor diversification incentives.

Contrarianly, the first post-IPO supply events demonstrate that lockup mechanics alone are not a deterministic short signal. Passive buying and retail scarcity can produce a squeeze before the larger release, particularly if the company reports another headline growth quarter. The bearish thesis is falsified if SPCX holds above the post-rebalance high while delivering material improvement in operating cash burn or capex-to-revenue intensity; that would indicate demand is absorbing new float rather than merely front-running index flows.

Key Decisions for Investors

• Use any strength into the Sept. 21 Nasdaq-100 rebalance to initiate a tactical SPCX short or put spread, targeting the post-Q3-results/unlock window; structure defined-risk options because passive-flow squeezes can be violent. A 15-25% downside over 1-3 months is plausible if earnings do not materially reset cash-flow expectations, versus a 10-15% squeeze risk before index demand clears.
• Do not short solely on the Sept. 24, Oct. 9, or Oct. 24 releases. Monitor daily traded value, short interest, securities-lending utilization, and block-sale disclosures; absent evidence that incremental float exceeds normal daily absorption, treat each date as an alert rather than a standalone catalyst.
• For existing SPCX longs, reduce exposure into the Q3 report unless management provides verifiable evidence of declining capital intensity and a credible path to positive operating cash flow. Retain upside only through call spreads rather than unhedged common stock until the large release is absorbed.
• Avoid using NDAQ as a direct sympathy long: the listing is strategically positive but unlikely to move exchange earnings materially. The cleaner expression is SPCX-specific, with NVDA serving only as a broad AI-duration hedge if portfolio beta requires it.